Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit J Arsenault

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
The American Journal of Cardiology|May 10, 2011
Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study)Mélanie Côté, Amélie Cartier, Anne Q Reuwer, et al.
International Journal of Cardiology|April 28, 2009
Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population studyJamal S Rana, Maartje E Visser, Benoit J Arsenault, et al.
Journal of the American College of Cardiology|February 2, 2010
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and womenBenoit J Arsenault, Jamal S Rana, Erik S G Stroes, et al.
European Heart Journal|November 6, 2018
Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosisRihab Bouchareb, Marie-Chloé Boulanger, Lionel Tastet, et al.
HGG Advances|May 7, 2025
Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targetsPardis Zamani, Ursula Houessou, Hasanga D Manikpurage, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Gastroenterology|February 3, 2023
Proteome-Wide Mendelian Randomization Identifies Causal Links Between Blood Proteins and Acute PancreatitisJérôme Bourgault, Erik Abner, Hasanga D Manikpurage, et al.
Atherosclerosis|June 23, 2017
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURNRishi Puri, Christie M Ballantyne, Ron C Hoogeveen, et al.
Heart (British Cardiac Society)|October 1, 2021
Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosisYannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, et al.
Communications Medicine|July 1, 2025
Appraisal of multiple polygenic risk scores to estimate the risk of myocardial infarction and coronary artery lesionsHasanga D Manikpurage, Jérôme Bourgault, Ursula Houessou, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
The American Journal of Cardiology|May 10, 2011
Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study)Mélanie Côté, Amélie Cartier, Anne Q Reuwer, et al.
International Journal of Cardiology|April 28, 2009
Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population studyJamal S Rana, Maartje E Visser, Benoit J Arsenault, et al.
Journal of the American College of Cardiology|February 2, 2010
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and womenBenoit J Arsenault, Jamal S Rana, Erik S G Stroes, et al.
European Heart Journal|November 6, 2018
Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosisRihab Bouchareb, Marie-Chloé Boulanger, Lionel Tastet, et al.
HGG Advances|May 7, 2025
Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targetsPardis Zamani, Ursula Houessou, Hasanga D Manikpurage, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Gastroenterology|February 3, 2023
Proteome-Wide Mendelian Randomization Identifies Causal Links Between Blood Proteins and Acute PancreatitisJérôme Bourgault, Erik Abner, Hasanga D Manikpurage, et al.
Atherosclerosis|June 23, 2017
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURNRishi Puri, Christie M Ballantyne, Ron C Hoogeveen, et al.
Heart (British Cardiac Society)|October 1, 2021
Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosisYannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, et al.
Communications Medicine|July 1, 2025
Appraisal of multiple polygenic risk scores to estimate the risk of myocardial infarction and coronary artery lesionsHasanga D Manikpurage, Jérôme Bourgault, Ursula Houessou, et al.
Pageof 16